<DOC>
	<DOCNO>NCT00650221</DOCNO>
	<brief_summary>The objective study compare rate extent absorption pravastatin sodium test formulation Pravastatin Sodium 80 mg Tablets versus reference Pravachol® 80 mg Tablets fast condition . Based result study , two 80 mg pravastatin tablet formulation demonstrate bioequivalence single-dose fasting condition .</brief_summary>
	<brief_title>Fasting Bioequivalence Study Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Subjects meet follow criterion may include study : Nonsmoking male female minimum age 18 year . Body Mass Index ( BMI = weight/height2 ) great equal 19 kg/m2 less equal 26 kg/m2 . Availability subject entire study period willingness adhere protocol requirement , evidence sign Informed Consent Form . Normal finding physical examination , 12‑lead ECG vital sign ( blood pressure 100‑140/60‑90 mmHg , heart rate 5099 beats/min temperature 35.8°C 37.5°C ) . Negative drug abuse , nicotine , alcohol , hepatitis Bsurface antigen , hepatitis C HIV , female subject , pregnancy ( serum ßCG ) . No clinical laboratory value outside acceptable range define BCR , unless Principal Investigator decide clinically significant . Female subject surgically sterile least six month postmenopausal least one year , avoid pregnancy prior study , study one month end study . Subjects meet follow criterion exclude : Known history hypersensitivity pravastatin sodium ( e.g . Pravachol® , Lipostat® ) and/or relate drug simvastatin ( Zocor® ) , atorvastatin ( Lipitor™ ) , cerivastatin ( Baycol® ) fluvastatin ( Lescol® ) . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological , liver kidney disease , unless judge clinically significant Principal Investigator , medical designate . Known history presence food allergy , condition know interfere absorption , distribution , metabolism excretion drug . Any clinically significant illness last four week prior entry study . Presence significant physical organ abnormality . Any subject history drug abuse . Any psychiatric psychological disease ( include depression ) unless deem clinically significant Principal Investigator , medical designate . Use prescription medication within 14 day precede entry study . Use overthecounter ( OTC ) medication within seven day precede entry study ( except spermicidal/barrier contraceptive product ) . Female subject : use oral contraceptive contraceptive implant ( Norplant® ) within 30 day prior drug administration depot injection progestogen drug ( e.g . DepoProvera® ) within one year prior drug administration . Female subject : presence pregnancy lactation . Any subject blood withdrawal within 56 day precede study , take conduct clinical study facility BCR , within lockout period specify previous study conduct BCR . Participation clinical trial investigational drug within 30 day precede study . Any subject donate blood within 56 day precede study . Any subject participate plasma donor plasmapheresis program within seven day precede study . Significant recent history asthma ( 12 year age ) . Any subject recent ( less one year ) history alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>